Mylan's shares rise, affecting Teva

Note: This section contains information in English only.
Source: Dukascopy Bank SA
The US approval of Mylan NV's MS treatment Copaxone, generic version of Teva's blockbuster, drove shares of the drugmaker up 19%, affecting rival's shares.

Actual Topics